Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

XmAb662

Fusion protein · Immune activation · developed by Xencor

Phase 1 Most advanced trial (none active)
XNCR Developer
1 Registered trials

What is XmAb662?

XmAb662 is an engineered, potency-reduced fusion protein of human interleukin-12 (IL-12) and an Fc domain. IL-12 activates CD8+ and CD4+ T-cells and natural killer cells, promoting interferon-gamma secretion and cytolytic immune responses. It is being studied in solid tumors, and the Fc domain prolongs its half-life and exposure in the tumor.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Fusion protein
Mechanism
Immune activation
Pathways
IFN-gamma secretion, CD8+ T-cell activation, CD4+ T-cell activation, natural killer cell activation
Therapy area
Oncology
Developer
Xencor, Inc. (XNCR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05996445 Phase 1 Solid Tumors Terminated XNCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Tumors

More from Xencor

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.

Follow XNCR, the company behind XmAb662

See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XNCR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.